Careers

Join Factor Bioscience and become part of a team working to invent new technologies to treat disease and improve health.

Our research lab and ISO Class 7 cleanroom facility are both located at our headquarters in Cambridge, Massachusetts.

Join Us

Associate Scientist

Posted on: 10-21-2021

Factor Bioscience is seeking an exceptional candidate to join our team as Associate Scientist. In this position, you will create advanced mRNA and cell-engineering technologies for the development of new medicines for patients with devastating diseases including Parkinson's disease, Crohn's disease, dystrophic epidermolysis bullosa, and cancer.

Associate Scientist (Chemistry)

Posted on: 10-21-2021

Factor Bioscience is seeking an exceptional candidate to join our team as Associate Scientist. In this position, you will create advanced mRNA and cell-engineering technologies for the development of new medicines for patients with devastating diseases including Parkinson's disease, Crohn's disease, dystrophic epidermolysis bullosa, and cancer.

Factor News

January 13, 2022

Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio

NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces that 18 new patents were issued and 17 new patent applications were filed in 2021. The intellectual property is owned by Factor Bioscience (“Factor”) and exclusively licensed to Brooklyn for various fields of therapeutic use. The newly-issued patents encompass those covering the Company’s mRNA-based cellular reprogramming and gene editing technology, as well as nucleic acid delivery using Brooklyn’s ToRNAdo™ lipid nanoparticle technology (LNP).

October 25, 2021

Factor Bioscience Joins Strategic Partner Brooklyn ImmunoTherapeutics to Ring the Nasdaq Closing Bell

CAMBRIDGE, Mass., Oct. 25, 2021 -- The executive leadership of Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies joined the leadership of Factor’s strategic partner, Brooklyn ImmunoTherapeutics (Nasdaq: BTX) today at the Nasdaq MarketSite in Times Square, New York, for the ringing of the Nasdaq closing bell by Brooklyn’s President and CEO, Howard J. Federoff, M.D., Ph.D. Factor Bioscience was represented by Co-Founder, Chairman, and CEO, Matt Angel, Ph.D., and Co-Founder and Chief Technology Officer, Christopher Rohde, Ph.D., while the Brooklyn team included Jay Sial, Chief Administrative Officer, Roger Sidhu, M.D., Chief Medical Officer, Ron Guido, M.S., M.S. Pharm. Med., Chief Development Officer, and Lynn Sadowski-Mason, M.S., EVP Clinical Operations.

October 21, 2021

Exacis Biotherapeutics Announces Strategic Partnership With CCRM For Specialty Manufacturing Of Services And Investment For Development Of iPSC-Derived mRNA-Engineered NK Cells

CAMBRIDGE, Mass., Oct. 21, 2021 /PRNewswire/ -- Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced initiation of a strategic partnership with Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM) for specialty manufacturing services related to the development of Exacis' innovative, iPSC-derived mRNA-engineered NK cell products to treat cancer. The partnership also includes a cash investment into Exacis by CCRM Enterprises Holdings Ltd., the for-profit venture investment arm of CCRM, which will be used to fund operations.